Reference Prgs

REFERENCE 1.Micheal J. Rathbone, Jonathan Hadgraft, Micheal S. Roberts , Majella E. Lane;” Modified Release drug delivery System”, II Edtion, Vol-I, Informa Healthcare, USA, 2008, 343-345. SITE {http://books.google.co.in/books? id=56TeYRI3LUMC&printsec=frontcover&source=gbs_v2_summary_r&cad=0#v=one page&q=&f=false} 2. http://en.wikipedia.org/wiki/Colon_%28anatomy%29 1. http://definr.com/large+intestine 2. http://wiki.answers.com/Q/What_are_the_lengths_of_the_different_parts_of_the_ colon 3. Mayo Clinic Staff (2006-10-13). "Redundant colon: A health concern?". Ask a Digestive System Specialist. MayoClinic.com. http://www.mayoclinic.com/health/redundant-colon/AN00239/rss=1. Retrieved 2007-06-11. 4. Lichtenstein, Gary R.; Peter D. Park, William B. Long, Gregory G. Ginsberg, Michael L. Kochman (18 August 1998). "Use of a Push Enteroscope Improves Ability to Perform Total Colonoscopy in Previously Unsuccessful Attempts at Colonoscopy in Adult Patients". The American Journal of Gastroenterology 94 (1): 187. doi:10.1111/j.1572-0241.1999.00794.x. PMID 9934753. Note:Single use PDF copy provided free by Blackwell Publishing for purposes of Wikipedia content enrichment. 3. http://www.pharmainfo.net/reviews/colon-targeted-pulsatile-drug-delivery-review 1. 2. 3. 4. 5. 6. 7. 8.

Gennaro AR , ed. Remington: The Science and Practice of Pharmacy. 20th ed. USA : Lippincott, Williams & Wilkins; 2000, 20:903-905. Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2001;18(5):433-58. Review. Das NG, Das SK. Controlled release of oral dosage forms, formulation, finish, and fill. www.pharmtech.com. 2003;10-16. Umang Pharmatech Pvt. Ltd., Umang offers Road to Pelletisation through spher’odization. Express Pharma Pulse, 2000. Gurny R, Junginger HE, Peppas N. Pulsatile Drug Delivery: Current Applications and Future Trends. Stuttgart , Germany : Wissenschaftliche Verlagsgesellschaft;1993. Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. Gastroenterol. 1987;93(3):515-518. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999;51:887-890. Dethlefsen U, Repges R. Ein neues therapieprinzip bei nächtlichem asthma. Med Klinik. 1985;80:44-47. 1

9.

Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci. 2003;6(1):33-66. 10. Lachman L, Lieberman HA, Kanig JL, The Theory and Practice of Industrial Pharmacy. Vol. 3. India : Verghese Publishing House; 1991. 11. Chang R-K, Guo X, Burside BA, Couch RA, Rudnic EM. Formulation approaches for oral pulsatile drug delivery. Amer Pharma Rev. 1999;2(1):51-57. 12. Petereit HU. Pulsed release drug delivery. www.iptonline.com. 2003:101-104. 13. Vinay kumar et al. Basic physiology. 5 th editon, W>B> saundres componey, 1992, 21. 14. Chang R.K. et al. American pharmaceutical review, 1999,21. 15. Lammer B. J Pharmacol. 51, 1999, 887. 16. Wilding IR, Davis SS, Bakhshaee M et al. Pharm Res, 9:654-657, 1992. 17. McNeil ME, Rashid A, Stevens HNE. Dispensing Device. WO Patent No. 90/09168 (1990). 18. Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm Res.1992;9:654-657. 19. Saeger H, Virley P. Pulsincap& Mac226: Pulsed-Release Dosage Form. Product information from Scherer DDS, Ltd; 2004. 20. Binns J, Stevens HNE, McEwen J, Pritchard G, Brewer FM, Clarke A, Johnson ES, McMillan I. The tolerability of multiple oral doses of Pulsincap & Mac226 capsules in healthy volunteers. J Control Rel. 1996;38:151-158. 21. Krögel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res. 1998;15(3):474-481. 22.  Krögel I, Bodmeier R. Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. Pharm Res. 1999;16(9):1424-1429. 23.  Crison JR, Siersma PR, Taylor MD, Amidon GL. Programmable oral release technology, Port Systems & Mac226: a novel dosage form for time and site specific oral drug delivery. Proceed Intern Symp Control Rel Bioact Mater. 1995;22:278-279. 24. Crison JR, Siersma PR, Amidon GL. A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy. Proceed Intern Symp Control Rel Bioact Mater. 1996;23:51-52. 25. Crison JR, Vieira ML, Kim J-S, Siersma C, Amidon GL. Pulse delivery of methylphenidate in dogs using an osmotic drug delivery system. Proceed Intern Symp Control Rel Bioact Mater. 2001;28:6101. 26.  Pollock-Dove C, Dong L, Wong P. A new system to deliver a delayed bolus of liquid drug formulation. Proceed Intern Symp Control Rel Bioact Mater. 2001;28:6033. 27. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,318,558; 1994. 28. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,221,278; 1993. 29. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically Driven Delivery Devices with Pulsatile Effect. US Patent No. 5209746; 1993.

2

30. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising Salbutamol. US Patent No. 4751071; 1988. 31. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Constant Release System with Pulsed Release. US Patent No. 4777049; 1988. 32. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising a Therapeutic Agent and a Modulating Agent. US Patent No. 4851229; 1989. 33. Pozzi F, Furlani P. Orale Feste Pharmazeutische Darreichungsform Mit Programmierter Freisetzung. DE Patent No. 4122039; 1992 5. http://www.jyoungpharm.in/article.asp?issn=0975- 1483;year=2009; volume=1; issue=1;spage =13;epage=19;aulast=Jose. 34. Jung YJ, Kim HH, Kim YK, Han SK. Synthesis and evaluation of 5-Amino salicylglycine as a potential colon specific prodrug of 5-ASA. Arch Pharmacol Res 1998;21:174-8. 35. Simpkins JW, Smulkowski M, Dixon R, Tuttle R. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988;244:195-205. 36. Cui N, Friend DR, Fedorak RN. A Budesonide prodrug accelerates treatment of colitis in rats. Gut 1994;35:1439-46. 37. Haeberlin B, Rubas W, Nolen HW, Friend DR. In vitro evaluation of dexamethasone-b-D-glucuronide for colon-specific drug delivery. Pharm Res 1993;10:1553-62. 38. Friend DR, Chang GW. Drug Glycosides: Potential prodrug for colon-specific drug delivery. J Med Chem 1985;28:51-7. 39. Andrew D, Thomas N. Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon specific delivery. Int Journal of Pharm 1993;92:105-14.

3